C1-INH (Hereditary angioedema):
C1 esterase inhibitor (C1-INH) is a blood protein that controls C1, the first component of the complement system, a complex network of proteins which are important in the body’s ability to resist infection. Congenital deficiency of C1-INH causes hereditary angioedema, Deficiency of C1-INH may rarely be acquired later in life, usually associated with white cell malignancies or autoimmune disease. The C1-INH protein is most commonly used for the treatment of hereditary angioedema (“HAE”), a rare genetic disorder in which C1-INH is lacking. HAE is a rare genetic disorder. It is characterized by spontaneous and recurrent episodes of swelling (edema attacks) of the skin in various parts of the body, as well as in the airways and internal organs.
HAE affects about 1 in 10,000 to 1 in 50,000 people worldwide. The world market reached US$1.1bn in 2014 and has been growing at an average rate of 44% in the last 3 years.
Prometic is currently scaling up C1-INH and anticipates filing an IND in 2017.